Triple therapy in patients with atrial fibrillation and acute coronary syndrome or percutaneous coronary intervention/stenting

被引：6

作者：

Koziel, Monika ^{[1
,2
,3
]}

Potpara, Tatjana S. ^{[4
,5
]}

Lip, Gregory Y. H. ^{[1
,2
,3
,5
,6
]}

机构：

[1] Univ Liverpool, Liverpool Ctr Cardiovasc Sci, William Henry Duncan Bldg,6 West Derby St, Liverpool L7 8TX, Merseyside, England

[2] Liverpool Heart & Chest Hosp, William Henry Duncan Bldg,6 West Derby St, Liverpool L7 8TX, Merseyside, England

[3] Med Univ Silesia, Dept Cardiol Congenital Heart Dis & Electrotherap, Div Med Sci Zabrze, Katowice, Poland

[4] Clin Ctr Serbia, Cardiol Clin, Belgrade, Serbia

[5] Univ Belgrade, Sch Med, Belgrade, Serbia

[6] Aalborg Univ, Dept Clin Med, Aalborg Thrombosis Res Unit, Aalborg, Denmark

来源：

RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS | 2020年 / 4卷 / 03期

关键词：

acute coronary syndrome; antiplatelets; atrial fibrillation; oral anticoagulation; percutaneous coronary intervention; triple therapy; ACUTE MYOCARDIAL-INFARCTION; VITAMIN-K ANTAGONISTS; ANTITHROMBOTIC THERAPY; OPEN-LABEL; ANTICOAGULANT-THERAPY; ORAL ANTICOAGULATION; ANTIPLATELET THERAPY; CONCOMITANT ASPIRIN; STENT IMPLANTATION; WARFARIN THERAPY;

D O I：

10.1002/rth2.12319

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Patients with atrial fibrillation (AF) and acute coronary syndrome (ACS) are at high risk of stroke, recurrent coronary ischemic events, and cardiovascular mortality. The composition of antithrombotic therapy including an oral anticoagulant and antiplatelet drug(s) should be tailored according to the individual patient's risk profile, to reduce the bleeding risk and maintain antithrombotic effect. There is no single antithrombotic treatment regimen that would fit to all patients with AF and ACS. However, available data promote the use of full-dose direct oral anticoagulants (DOACs) (dabigatran 150 mg twice daily or apixaban 5 mg twice daily) or rivaroxaban 15 mg once daily in patients with AF and ACS or percutaneous coronary intervention (PCI). For many patients, a DOAC plus P2Y(12) inhibitor early after ACS and/or PCI would be optimal, whereas a longer course of triple therapy should be used in patients at high thrombotic risk.

引用

页码：357 / 365

页数：9

共 66 条

[1]

Abdulrehman J, 2019, RES PRACT THROMB HAE, P733

[2] Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial [J].

Alexander, John H. ;

Lopes, Renato D. ;

Thomas, Laine ;

Alings, Marco ;

Atar, Dan ;

Aylward, Philip ;

Goto, Shinya ;

Hanna, Michael ;

Huber, Kurt ;

Husted, Steen ;

Lewis, Basil S. ;

McMurray, John J. V. ;

Pais, Prem ;

Pouleur, Hubert ;

Steg, Philippe Gabriel ;

Verheugt, Freek W. A. ;

Wojdyla, Daniel M. ;

Granger, Christopher B. ;

Wallentin, Lars .

EUROPEAN HEART JOURNAL, 2014, 35 (04) :224-232

[3] Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention A North American Perspective-2016 Update [J].

Angiolillo, Dominick J. ;

Goodman, Shaun G. ;

Bhatt, Deepak L. ;

Eikelboom, John W. ;

Price, Matthew J. ;

Moliterno, David J. ;

Cannon, Christopher P. ;

Tanguay, Jean-Francois ;

Granger, Christopher B. ;

Mauri, Laura ;

Holmes, David R. ;

Gibson, C. Michael ;

Faxon, David P. .

CIRCULATION-CARDIOVASCULAR INTERVENTIONS, 2016, 9 (11)

[4] New-Onset Atrial Fibrillation is Associated With Cardiovascular Events Leading to Death in a First Time Myocardial Infarction Population of 89 703 Patients With Long-Term Follow-Up: A Nationwide Study [J].

Bang, Casper N. ;

Gislason, Gunnar H. ;

Greve, Anders M. ;

Bang, Christian A. ;

Lilja, Alexander ;

Torp-Pedersen, Christian ;

Andersen, Per K. ;

Kober, Lars ;

Devereux, Richard B. ;

Wachtell, Kristian .

JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2014, 3 (01) :e000382

[5] Atrial Fibrillation, Stroke Risk, and Warfarin Therapy Revisited A Population-Based Study [J].

Bjorck, Staffan ;

Palaszewski, Bo ;

Friberg, Leif ;

Bergfeldt, Lennart .

STROKE, 2013, 44 (11) :3103-3108

[6] Predicting Thromboembolic and Bleeding Event Risk in Patients with Non-Valvular Atrial Fibrillation: A Systematic Review [J].

Borre, Ethan D. ;

Goode, Adam ;

Raitz, Giselle ;

Shah, Bimal ;

Lowenstern, Angela ;

Chatterjee, Ranee ;

Sharan, Lauren ;

LaPointe, Nancy M. Allen ;

Yapa, Roshini ;

Davis, J. Kelly ;

Lallinger, Kathryn ;

Schmidt, Robyn ;

Kosinski, Andrzej ;

Al-Khatib, Sana M. ;

Sanders, Gillian D. .

THROMBOSIS AND HAEMOSTASIS, 2018, 118 (12) :2171-2187

[7] Factor XI Antisense Oligonucleotide for Prevention of Venous Thrombosis [J].

Bueller, Harry R. ;

Bethune, Claudette ;

Bhanot, Sanjay ;

Gailani, David ;

Monia, Brett P. ;

Raskob, Gary E. ;

Segers, Annelise ;

Verhamme, Peter ;

Weitz, Jeffrey I. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (03) :232-240

[8] Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation [J].

Cannon, Christopher P. ;

Bhatt, Deepak L. ;

Oldgren, Jonas ;

Lip, Gregory Y. H. ;

Ellis, Stephen G. ;

Kimura, Takeshi ;

Maeng, Michael ;

Merkely, Bela ;

Zeymer, Uwe ;

Gropper, Savion ;

Nordaby, Matias ;

Kleine, Eva ;

Harper, Ruth ;

Manassie, Jenny ;

Januzzi, James L. ;

ten Berg, Jurrien M. ;

Steg, Gabriel ;

Hohnloser, Stefan H. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (16) :1513-1524

[9] Management of Antiplatelet and Anticoagulant Therapy in Patients With Atrial Fibrillation in the Setting of Acute Coronary Syndromes or Percutaneous Coronary Interventions [J].

Capodanno, Davide ;

Angiolillo, Dominick J. .

CIRCULATION-CARDIOVASCULAR INTERVENTIONS, 2014, 7 (01) :113-124

[10] Incident Risk Factors and Major Bleeding in Patients with Atrial Fibrillation Treated with Oral Anticoagulants: A Comparison of Baseline, Follow-up and Delta HAS-BLED Scores with an Approach Focused on Modifiable Bleeding Risk Factors [J].

Chao, Tze-Fan ;

Lip, Gregory Y. H. ;

Lin, Yenn-Jiang ;

Chang, Shih-Lin ;

Lo, Li-Wei ;

Hu, Yu-Feng ;

Tuan, Ta-Chuan ;

Liao, Jo-Nan ;

Chung, Fa-Po ;

Chen, Tzeng-Ji ;

Chen, Shih-Ann .

THROMBOSIS AND HAEMOSTASIS, 2018, 118 (04) :768-777

← 1 2 3 4 5 6 7 →